Home・Aandelen Lijst・Arvinas Inc

Arvinas Inc

Gesloten

SectorGezondheidszorg

8.24 0.12

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

7.87

Max

8.28

Belangrijke statistieken
By Trading Economics
Inkomsten	9.8M -58M
Verkoop	6.1M 16M
EPS	-0.9
Winstmarge	-369.231
Werknemers	246
EBITDA	9.6M -56M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+82.81% upside

Dividenden
By Acuity
Volgende Winsten	5 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-106M 517M
Vorige openingsprijs	8.12
Vorige sluitingsprijs	8.24

Nieuwssentiment

By Acuity

60%

40%

284 / 340 Rangschikking in Healthcare

Arvinas Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 jul 2026, 20:06 UTC

Arvinas Inc shares are higher during Tuesday's session, tracking gains in the Nasdaq 100 Index amid strong technology sector performance. No specific news was identified.

Peer Vergelijking

Prijswijziging

Arvinas Inc Prognose

Koersdoel

By TipRanks

82.81% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 15.1 USD 82.81%

Hoogste 24 USD

Laagste 6 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Arvinas Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Arvinas Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

284 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.